Table 1.
Quantitative evaluation of neoplastic lesions in prostates of TRAP rats treated with PCC
| No. of animal | Incidence of adenocarcinoma | Proportion of acini in different stages of carcinogenesis (%) | |||
|---|---|---|---|---|---|
| LG‐PIN | HG‐PIN | Adenocarcinoma | |||
| Ventral prostate | |||||
| Control | 13 | 13 (100%) | 4.4 ± 2.8 | 89.2 ± 3.5 | 6.4 ± 4.0 |
| 0.1% PCC | 12 | 12 (100%) | 5.9 ± 3.4** | 90.6 ± 3.8 | 3.5 ± 1.7*** |
| 1% PCC | 11 | 11 (100%) | 9.1 ± 3.9** | 88.2 ± 3.4 | 2.7 ± 2.0*** |
| Lateral prostate | |||||
| Control | 13 | 12 (92%) | 24.7 ± 12.4 | 72.8 ± 11.7 | 2.5 ± 2.8 |
| 0.1% PCC | 12 | 7 (58%) | 17.8 ± 5.6 | 81.2 ± 5.6 | 1.0 ± 1.0** |
| 1% PCC | 11 | 3 (27%)* | 21.1 ± 6.8 | 78.0 ± 6.2 | 0.9 ± 1.6** |
AC, adenocarcinoma; HG, high grade; LG‐PIN, low grade prostatic intraepithelial neoplasia. *P < 0.01 versus control (Dunnett's test). **P < 0.01 and ***P < 0.001 versus control, respectively (Spearman's rank correlation coefficient analysis).